BRPI0810524A2 - Derivado de (aza)indol e uso do mesmo para propósitos médicos - Google Patents

Derivado de (aza)indol e uso do mesmo para propósitos médicos

Info

Publication number
BRPI0810524A2
BRPI0810524A2 BRPI0810524-3A2A BRPI0810524A BRPI0810524A2 BR PI0810524 A2 BRPI0810524 A2 BR PI0810524A2 BR PI0810524 A BRPI0810524 A BR PI0810524A BR PI0810524 A2 BRPI0810524 A2 BR PI0810524A2
Authority
BR
Brazil
Prior art keywords
aza
same
medical purposes
indol derivative
indol
Prior art date
Application number
BRPI0810524-3A2A
Other languages
English (en)
Inventor
Kazuo Shimizu
Yasushi Takigawa
Hideki Fujikura
Masato Iizuka
Masahiro Hiratochi
Norihiko Kikuchi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BRPI0810524A2 publication Critical patent/BRPI0810524A2/pt
Publication of BRPI0810524B1 publication Critical patent/BRPI0810524B1/pt
Publication of BRPI0810524B8 publication Critical patent/BRPI0810524B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0810524A 2007-04-11 2008-04-10 derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado BRPI0810524B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007104096 2007-04-11
PCT/JP2008/057089 WO2008126898A1 (ja) 2007-04-11 2008-04-10 （アザ）インドール誘導体及びその医薬用途

Publications (3)

Publication Number Publication Date
BRPI0810524A2 true BRPI0810524A2 (pt) 2014-10-21
BRPI0810524B1 BRPI0810524B1 (pt) 2019-09-10
BRPI0810524B8 BRPI0810524B8 (pt) 2021-05-25

Family

ID=39863993

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810524A BRPI0810524B8 (pt) 2007-04-11 2008-04-10 derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado

Country Status (18)

Country Link
US (4) US8003647B2 (pt)
EP (2) EP2133332B1 (pt)
JP (1) JP5330989B2 (pt)
KR (1) KR101502957B1 (pt)
CN (1) CN101679251B (pt)
AU (1) AU2008239017B2 (pt)
BR (1) BRPI0810524B8 (pt)
CA (1) CA2682391C (pt)
CY (1) CY1114647T1 (pt)
DK (1) DK2133332T3 (pt)
ES (1) ES2431815T3 (pt)
HR (1) HRP20130900T1 (pt)
MX (1) MX337527B (pt)
PL (1) PL2133332T3 (pt)
PT (1) PT2133332E (pt)
RU (1) RU2477274C2 (pt)
SI (1) SI2133332T1 (pt)
WO (1) WO2008126898A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
BRPI1013432B1 (pt) 2009-03-31 2019-12-17 Kissei Pharmaceutical derivado de indolizina e composição farmacêutica
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
KR20130099064A (ko) * 2010-09-29 2013-09-05 깃세이 야쿠힌 고교 가부시키가이샤 (아자)인돌리진 유도체 및 그 의약용도
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
KR20140060535A (ko) * 2011-08-24 2014-05-20 깃세이 야쿠힌 고교 가부시키가이샤 축합 헤테로환 유도체 및 그 의약용도
JPWO2013061962A1 (ja) * 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN103980267B (zh) * 2013-02-08 2018-02-06 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
WO2014132994A1 (ja) * 2013-02-27 2014-09-04 キッセイ薬品工業株式会社 含窒素複素環誘導体の製造方法およびその製造中間体
WO2015025914A1 (ja) * 2013-08-22 2015-02-26 キッセイ薬品工業株式会社 インドール誘導体の塩及びその結晶
JP6823359B2 (ja) * 2014-06-09 2021-02-03 キッセイ薬品工業株式会社 インドール誘導体の塩及びその結晶
HUE052608T2 (hu) 2015-09-02 2021-05-28 Sunshine Lake Pharma Co Ltd Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
NZ749427A (en) * 2016-05-23 2019-11-29 Cstone Pharmaceutical Suzhou Co Ltd Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106045898B (zh) * 2016-06-28 2019-05-24 广东东阳光药业有限公司 一种吲哚类化合物及其制备方法和用途
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN107501162B (zh) * 2017-07-07 2021-06-25 浙江工业大学 一种n-酰基取代的吲哚衍生物的制备方法
CN107987006B (zh) * 2017-12-20 2021-06-01 华润赛科药业有限责任公司 吲哚类或氮杂吲哚类衍生物、其制备方法和应用
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2021083319A1 (zh) * 2019-10-30 2021-05-06 南京明德新药研发有限公司 作为黄嘌呤氧化酶抑制剂的噻吩衍生物及其应用
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
MX2023003677A (es) * 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CA3194595A1 (en) * 2020-11-04 2022-05-12 Seok Ju Lee Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
KR20220077091A (ko) * 2020-12-01 2022-06-08 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
PE20240764A1 (es) * 2021-04-16 2024-04-17 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
KR20220147531A (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
US20240262809A1 (en) * 2021-04-27 2024-08-08 Lg Chem, Ltd. Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
TWI901895B (zh) * 2021-06-15 2025-10-21 南韓商Ｌｇ化學股份有限公司 一種包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸的醫藥組成物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TWI922802B (zh) * 2022-04-27 2026-04-21 大陸商杭州新元素藥業股份有限公司 可用於痛風的化合物
CN120398899A (zh) * 2024-01-30 2025-08-01 深壶制药(山东)有限公司 二氢呋喃并吲哚类化合物或其衍生物及其应用
WO2025223330A1 (zh) * 2024-04-23 2025-10-30 深壶制药(山东)有限公司 吲哚并饱和环类化合物或其衍生物及其应用
CN118598859B (zh) * 2024-05-21 2025-08-19 武汉工程大学 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用
WO2026026716A1 (zh) * 2024-07-30 2026-02-05 深壶制药(山东)有限公司 恶唑或噻唑并吲哚类化合物或其衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JP2000001431A (ja) * 1998-06-15 2000-01-07 Kotobuki Seiyaku Kk 尿酸排泄剤
WO2002004440A1 (en) 2000-07-10 2002-01-17 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
JP4951517B2 (ja) 2005-09-30 2012-06-13 三菱伸銅株式会社 溶融固化処理物並びに溶融固化処理用銅合金材及びその製造方法
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途

Also Published As

Publication number Publication date
BRPI0810524B1 (pt) 2019-09-10
WO2008126898A1 (ja) 2008-10-23
CN101679251A (zh) 2010-03-24
MX337527B (es) 2016-03-09
KR101502957B1 (ko) 2015-03-16
CA2682391A1 (en) 2008-10-23
US8829040B2 (en) 2014-09-09
JPWO2008126898A1 (ja) 2010-07-22
US20110230454A1 (en) 2011-09-22
PT2133332E (pt) 2013-10-03
EP2402314A1 (en) 2012-01-04
CN101679251B (zh) 2013-10-02
CA2682391C (en) 2014-07-08
SI2133332T1 (sl) 2014-02-28
MX2009010966A (es) 2009-11-02
US8003647B2 (en) 2011-08-23
BRPI0810524B8 (pt) 2021-05-25
HRP20130900T1 (hr) 2013-11-08
AU2008239017A1 (en) 2008-10-23
KR20090128488A (ko) 2009-12-15
JP5330989B2 (ja) 2013-10-30
EP2133332B1 (en) 2013-09-18
US8466152B2 (en) 2013-06-18
CY1114647T1 (el) 2016-12-14
ES2431815T3 (es) 2013-11-28
RU2009141614A (ru) 2011-05-20
PL2133332T3 (pl) 2014-02-28
US20130252955A1 (en) 2013-09-26
HK1140197A1 (en) 2010-10-08
AU2008239017B2 (en) 2012-09-27
US20140179932A1 (en) 2014-06-26
RU2477274C2 (ru) 2013-03-10
DK2133332T3 (da) 2013-09-30
US20100056521A1 (en) 2010-03-04
EP2402314B1 (en) 2013-07-31
US8993616B2 (en) 2015-03-31
EP2133332A4 (en) 2011-05-25
EP2133332A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
CR10583A (es) Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
PL2133332T3 (pl) Pochodna aza(indolu) i jej zastosowanie do celów medycznych
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0820556A2 (pt) Bactéria e métodos para uso das mesmas
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0812944A2 (pt) Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI0813457A2 (pt) Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.